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geﬁ tinib versus all doublet chemotherapies (geﬁ tinib vs. pemetrexed/cisplatin OR 3.05, 
95% CrI: 1.58–5.51). CONCLUSIONS: This adjusted indirect comparison suggests 
that geﬁ tinib may have important ORR advantages over other ﬁ rst-line treatments in 
EGFR-TK M+ patients.
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OBJECTIVES: Standard ﬁ rst-line treatment for patients with mHRPC is Docetaxel(D)-
based chemotherapy. Published results from randomized clinical trials of second-line 
treatments after D failed to provide deﬁ nitive conclusions about clinical efﬁ cacy largely 
due to paucity of data. This study sought to identify nonrandomized trials of second-
line chemotherapy in mHRPC patients pretreated with D and present related survival 
and clinical beneﬁ ts. METHODS: Pubmed and Embase were used to perform a sys-
tematic literature review (SLR) (2000–2010). Both comparative and noncomparative 
nonrandomized evidence were extracted from prospective and retrospective studies. 
Targeted population was patients with mHRPC failing previous D-based regimens. 
End points included overall-survival (OS), progression-free-survival (PFS), and PSA-
response rate. RESULTS: Among the 825 records screened, 30 studies met the inclu-
sion criteria, two of which were comparative. Of these, 10 addressed rechallenge with 
D and seven addressed mitoxantrone (MTX); the remaining 18 studies considered 
various other regimens. Treatment was with either single-agent or combination regi-
mens. Ninety-three percent of studies included <50 patients. PFS and PSA response 
deﬁ nitions varied between trials. For studies evaluating rechallenge with D, the median 
OS and PFS varied from 41 to 76 weeks and from 15 to 39 weeks respectively. For 
MTX, the median OS and PFS varied from 39 to 48 weeks and 13 to 16 weeks, 
respectively. For other chemotherapy regimens, the median OS and PFS varied from 
51 to 104 weeks and 9 to 17 weeks, respectively. PSA response rates varied from 24% 
to 70% to D rechallenge, from 4% to 33% to MTX-based regimens and from 0% to 
60% to other regimens. CONCLUSIONS: The SLR showed a lack of available non-
randomized evidence, and among the selected studies, evidence was not strong enough 
due to small sample sizes, noncomparative nature and variable PFS and PSA response 
deﬁ nitions. This literature review demonstrates that it is difﬁ cult to infer the clinical 
efﬁ cacy of mHRPC 2nd line chemotherapy.
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OBJECTIVES: Patients with breast cancer (BC) and bone metastases are at risk for 
skeletal-related events (SREs) that are associated with signiﬁ cant morbidity, mortality, 
and reduced quality of life. The intravenous bisphosphonates (IVBPs) zoledronic acid 
(ZOL) and pamidronate (PAM) are approved for treating patients with bone metas-
tases from BC. We compared incidence of SREs and mortality in women with BC who 
received ZOL or PAM, and assessed the long-term beneﬁ t of ZOL in a real-world 
setting. METHODS: A claims-based analysis of commercial and Medicare Advantage 
data from >45 US managed care plans was used to evaluate SRE rates and mortality 
in patients treated with ZOL or PAM. Inclusion criteria were age >18 years, BC with 
bone metastasis diagnosis between 01/01/01 and 12/31/06, continuous enrollment in 
the health plan, no evidence of bone metastasis or IVBP for 6 months before an index 
date of ﬁ rst receipt of ZOL or PAM. Patients were followed until disenrollment 
(including mortality) or study completion (12/31/07). Persistency was deﬁ ned as the 
absence of a >45-day gap between treatments. SREs were deﬁ ned as evidence of 
pathologic fracture, spinal cord compression, and radiotherapy or surgery to bone. 
RESULTS: Among 8757 patients (mean age, 58.1 ± 12.4 years) approximately 30% 
received ZOL, 15% received PAM, and 55% received no IVBP. Longer persistency 
with ZOL was associated with lower risk of fracture and of all SREs versus shorter 
persistency (trend test, P = 0.0026 and P = 0.0216, respectively). ZOL-treated patients 
had a moderately lower SRE incidence (36.2 vs. 40.0 per 100 person-years; P = 
0.0707) and signiﬁ cantly fewer deaths (6.2 vs. 8.9 per 100 person-years; P = 0.0130) 
versus PAM-treated patients. CONCLUSIONS: In a real-world assessment of women 
with bone metastases from BC, ZOL reduced SRE incidence and signiﬁ cantly 
improved survival versus PAM. Longer ZOL persistency was associated with lower 
SRE risk, reinforcing the importance of regular monthly ZOL dosing.
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OBJECTIVES: To assess the clinical consequences of primary prophylaxis (PP) with 
pegﬁ lgrastim versus 6- or 11-day ﬁ lgrastim (F6, F11) in the prevention of febrile 
neutropenia (FN) in non-Hodgkin lymphoma (NHL) patients receiving CHOP-14 
chemotherapy and in breast cancer (BC) patients receiving TAC chemotherapy in 
Germany. METHODS: A lifetime Markov model was developed, consisting of two 
phases: 1) on-chemotherapy phase (OCP), where model cycle length equals chemo-
therapy cycle length (CHOP-14:14 days, TAC: 21 days), and 2) post-chemotherapy 
phase (PCP) with annual model cycles. PP is deﬁ ned as prophylaxis initiated with the 
ﬁ rst chemotherapy cycle. Cycle 1 FN risk with no prophylaxis (NP) was estimated to 
be 21% for NHL CHOP-14 and 14% for BC TAC. All cycle relative risk of FN using 
PP with pegﬁ lgrastim versus no PP, F6, and F11 was 0.25, 0.87, and 0.61. FN case 
fatality was estimated (NHL: 8.9%; BC: 3.6%). In PCP, all-cause mortality was 
estimated from German life-tables; NHL and BC mortality from US data; patients 
experiencing FN were assumed to have higher mortality due to reduced chemotherapy 
dose intensity. All inputs were estimated from clinical trials and published literature. 
The model estimates life-years, number of FNs, and number needed to treat (NNT) 
to prevent an FN. RESULTS: NNT to prevent an FN were 1.3, 6.2, 2.2 in NHL; 2.3, 
11.1, 4.0 in BC for Pegﬁ lgrastim, F6, and F11 compare to NP. Overall, FN episodes 
per patient were 0.15, 0.76, and 0.47 in NHL; 0.09, 0.43, and 0.27 in BC. Per-patient 
life-months gained using PP with Pegﬁ lgrastim were 3.4 and 1.8 versus F6 and F11, 
respectively in NHL, and 2.2 and 1.2 in BC. CONCLUSIONS: Primary prophylaxis 
with pegﬁ lgrastim results in a lower NNT, fewer FN events, and more life-years than 
with 6-day ﬁ lgrastim or 11-day ﬁ lgrastim in both NHL and BC.
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OBJECTIVES: To undertake a systematic review of lapatinib plus letrozole (LAP + 
LET) with other ﬁ rst-line treatments for HR+ HER2+ advanced or MBC in postmeno-
pausal women who have not received prior therapy for advanced or metastatic disease. 
METHODS: Seven databases were searched through January 2009 for randomized 
controlled trials. Relevant interventions were lapatinib (alone/in combination), aro-
matase inhibitors (letrozole (LET), anastrozole (ANA), exemestane (EXE)), tamoxifen 
(TAM), and trastuzumab (TRAS) (alone/in combination). Outcomes included overall 
survival (OS), progression-free survival (PFS), time to progression (TTP), and objective 
response rate (ORR). From the available evidence, it was possible to directly compare 
LAP + LET with LET. Using a network meta-analysis, LAP + LET could be indirectly 
compared with the four other interventions. RESULTS: Eighteen studies (62 papers) 
met the inclusion criteria. LAP + LET was signiﬁ cantly superior to LET based on a 
direct head-to-head study in terms of PFS/TTP and ORR. In the indirect comparison 
with LAP + LET, TAM (hazard ratio [HR] = 0.45 [95% CI: 0.32, 0.65]), EXE (HR 
= 0.52 [0.34, 0.79]), and ANA (HR = 0.53 [0.36, 0.80]) scored signiﬁ cantly worse in 
terms of PFS/TTP and ORR (TAM: odds ratio [OR] = 0.25 [0.12, 0.53], ANA: OR 
= 0.27 [0.12, 0.58], EXE: OR = 0.47 [0.20, 1.09]). LAP + LET also seemed better, 
although not signiﬁ cantly, in terms of OS versus TAM: HR = 0.74 (0.49, 1.12), EXE: 
HR = 0.65 (0.39, 1.11), and ANA: HR = 0.71 (0.45, 1.14). LAP + LET when indirectly 
compared with TRAS + ANA, seemed to be better in terms of OS (HR = 0.85 [0.47, 
1.54]), PFS/TTP (HR = 0.89 [0.54, 1.47]) and ORR (OR = 0.92 [0.24, 3.48]), 
although, none of these results were signiﬁ cant. CONCLUSIONS: Using indirect 
methods, LAP + LET appeared to be the best treatment in this HR+ HER2+ patient 
population. However, the results are based on a network analysis for which the basic 
assumptions of homogeneity, similarity, and consistency were not fulﬁ lled. Therefore, 
despite the fact that these are the best available data, the results need to be interpreted 
with caution.
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OBJECTIVES: To compare the efﬁ cacy in progression-free survival (PFS) of bevaci-
zumab plus cisplatin and gemcitabine (BCG) and bevacizumab plus carboplatin and 
paclitaxel (BCP), relative to doublet-chemotherapy combinations for the treatment of 
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ﬁ rst-line advanced or metastatic NSCLC. METHODS: A systematic literature review 
identiﬁ ed randomized controlled trials (RCTs) reporting PFS for bevacizumab-based 
and doublet-chemotherapy combinations. Studies were evaluated for comparability of 
design and patient population. Reported PFS hazard ratios (HR) were analyzed simul-
taneously with a Bayesian mixed treatment comparison. The base-case analysis com-
pared BCG and BCP with grouped platinum-based doublets (PLD) and grouped 
nonplatinum-based doublets (NPLD). Scenario analyses explored BCP and BCG 
versus different combinations of doublet treatments. RESULTS: Eight identiﬁ ed RCTs, 
considered comparable in design and patient characteristics, allowed for a comparison 
between bevacizumab-based therapies and grouped doublet-chemotherapy combina-
tions. The expected PFS HRs relative to PLD, for BCP, BCG, and NPLD were 0.66 
(95% interval: 0.57; 0.77), 0.80 (0.71; 0.89), and 1.05 (0.92; 1.19), respectively. BCP 
and BCG were ranked as the top two most efﬁ cacious treatments in terms of PFS 
across all included regimens. Scenario analyses conﬁ rmed the top ranking for BCP and 
BCG. When BCP and BCG were compared to individual doublet chemotherapies, BCP 
showed the greatest beneﬁ t (HR of 0.63 [0.45; 0.88]), followed by BCG 7.5 mg/kg 
(0.75 [0.64; 0.87]) and BCG 15 mg/kg (0.85 [0.73; 0.99]). Further analyses conﬁ rmed 
the robustness of the ﬁ ndings. CONCLUSIONS: Compared to all available doublet-
chemotherapy combinations, bevacizumab-based therapy is expected to be more efﬁ -
cacious in terms of PFS, and could therefore be considered as the ﬁ rst treatment option 
in advanced or metastatic NSCLC.
PCN17
NO CONCLUSIVE EVIDENCE FROM RANDOMIZED CONTROLLED 
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OBJECTIVES: A docetaxel (D)-based regimen is recommended ﬁ rst-line treatment for 
mHRPC patients. Currently, there are no recommended second-line treatments for D 
pretreated patients. This study sought to identify phase II and III RCTs of second-line 
treatments for mHRPC in D pretreated patients to provide information regarding 
survival. METHODS: PubMed and Embase were used to perform a systematic litera-
ture review (2000–2009). Primary and secondary efﬁ cacy end points were extracted. 
Safety outcomes were reviewed according to grade. RESULTS: Among 52 records 
screened, three trials were included and 47 were excluded (35 not clinical trials; four 
not second line to D; eight not comparative or randomized). Primary end points 
included overall survival (OS), progression-free-survival (PFS), PSA response rate, and 
objective tumor response (OTR). a phase III study comparing satraplatin plus pred-
nisone (SP) to prednisone (P) alone (n = 950, 51% post-D) was identiﬁ ed. Two phase 
II trials compared ixabepilone (ixa) with mitoxantrone plus prednisone (MP) (n = 82), 
and custirsen in combination with prednisone plus D (DPC) versus curtisen plus MP 
(MPC) (n = 42). SP demonstrated signiﬁ cant improvements compared to P in PSA 
response (25% vs. 12%, P < 0.001), OTR (7% vs. 1%, P < 0.002), and pain response 
(24% vs. 14%, P < 0.005). Median PFS (11 weeks vs. 9.7 weeks), but median OS 
(66.1 weeks vs. 62.9 weeks) were similar. In the second trial (Ixa vs. MP), there was 
no signiﬁ cant improvement in either PSA response (17% vs. 20%) or OS. In the third 
trial, PSA response was better for DPC than MPC (40% vs. 27%); no OS data 
reported. Grade 3 or 4 neutropenia occurred in 54% and 63% with Ixa and MP 
respectively. CONCLUSIONS: This review found a limited number of published phase 
II and III RCTs second-line treatments for mHRPC in D pretreated patients. None 
demonstrated a survival beneﬁ t. Results should be interpreted with caution in terms 
of clinical beneﬁ ts.
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OBJECTIVES: Patients with bone metastases from prostate cancer (PC) are at risk for 
skeletal-related events (SREs) including pathologic fracture, spinal cord compression, 
the need for radiotherapy or surgery to bone, and hypercalcemia of malignancy. 
Zoledronic acid (ZOL), an intravenous bisphosphonate (IVBP), has proven efﬁ cacy 
for reducing the incidence and delaying the onset of SREs in multiple tumor types. 
This retrospective study was designed to assess the fracture risk in patients receiving 
ZOL or no treatment, and to examine the beneﬁ t of long-term ZOL use in a real-world 
setting among men with PC and bone metastases. METHODS: Commercial and 
Medicare Advantage databases were used to evaluate fracture rates and medication 
persistency. Patients included in this analysis were ≥18 years old, had PC and bone 
metastasis diagnosed between January 1, 2001 and December 31, 2006, were continu-
ously enrolled in the health plan, and had no evidence of bone metastasis or IVBP for 
6 months before ﬁ rst infusion of ZOL. Patients were followed until discontinuation 
(including mortality) or study completion. Fractures were categorized as vertebral, 
hip, or other nonvertebral fractures. Persistency was deﬁ ned as the absence of a 
>45-day gap between ZOL treatments. RESULTS: Among 4976 men (mean age, 70.9 
± 9.7 years), approximately 26% received ZOL and 74% received no IVBP. Regardless 
of fracture site, ZOL reduced the fracture rate compared with no IVBP (5.9 vs. 8.5 
per 100 person-years; P = 0.0003). Longer persistency with ZOL was associated with 
a reduced fracture rate (trend test, P = 0.0179). The mortality rate was also signiﬁ -
cantly lower in ZOL patients versus patients receiving no IVBP (6.2 vs. 9.4 per 100 
person-years; P = 0.0018). CONCLUSIONS: In men with bone metastases from PC, 
ZOL was associated with a signiﬁ cantly lower fracture rate and mortality compared 
with no IVBP. Furthermore, longer persistency with ZOL was associated with a lower 
fracture rate.
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OBJECTIVES: Endoscopic submucosal dissection (ESD) allows en bloc resection of 
the entire lesion which permits higher curative resection rate, lower local recurrence, 
and consequently, increases quality of life by minimizing the resection size compared 
to endoscopic mucosal resection (EMR). While ESD has been implemented in most 
university hospitals in Korea currently, potential complications of ESD like hemor-
rhage and perforation waver over the therapeutic decision on the ESD for early gastric 
cancer patients as well as the reimbursement decision-making. The study aims to 
address both effectiveness and safety outcomes of ESD versus EMR in early gastric 
cancer by systematic review. METHODS: MEDLINE, EMBASE, Cochrane Central 
Register of Controlled Trials (CENTRAL), and Koreamed were searched using 
primary key words: “stomach neoplasm” and “endoscopic submucosal dissection” 
and “endoscopic mucosal resection.” To assess the quality of selected studies, the 
methodological approach of Scottish Intercollegiate Guidelines Network were used. 
Five effectiveness-relevant and three safety-relevant outcome measures were extracted. 
Bibliography management and meta-analysis for each outcome were conducted using 
Review Manager 5.0. RESULTS: Three nonconcurrent cohort studies and nine retro-
spective cohort studies were identiﬁ ed. Meta-analyses showed signiﬁ cantly greater 
effectiveness of ESD as compared to EMR for en bloc resection (OR = 8.43, 95% CI: 
5.20–13.67), complete resection (OR = 8.54, 95% CI: 4.44–16.45), curative resection 
(OR = 2.56, 95% CI: 1.68–3.91), local recurrence (RR = 0.13, 95% CI: 0.04–0.40), 
and all-cause mortality (RR = 0.65, 95% CI: 0.08–5.38). While intraoperative bleed-
ing (RR = 2.16, 95% CI: 1.14–4.09) and perforation risk (RR = 3.58, 95% CI: 
1.95–6.55) were signiﬁ cantly greater for ESD, overall bleeding risk (RR = 1.22, 95% 
CI: 0.76–1.98) and longer resection time (RR = 1.55, 95% CI: 0.74–2.37) were not 
signiﬁ cantly different between ESD and EMR. CONCLUSIONS: Considering bleeding 
risk was not signiﬁ cantly different between ESD and EMR, and the perforation risk 
usually does not lead to life-threatening disease, the effectiveness beneﬁ t of ESD can 
overweigh the overall harm compared to EMR on condition that ESD was performed 
by surgeons with certain experiences.
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OBJECTIVES: Recent clinical trials have established superior efﬁ cacy of both erlotinib 
and pemetrexed as ﬁ rst-line maintenance therapies for metastatic non-small cell lung 
cancer (mNSCLC) over placebo. Results indicated that erlotinib improved survival for 
all histology types and pemetrexed improved survival in nonsquamous patients. To 
date, there have been no head-to-head trials directly comparing the two agents. An 
indirect comparison analysis was performed to examine the relative efﬁ cacy of these 
two treatment regimens as maintenance treatment options following platinum-based 
ﬁ rst-line therapy. METHODS: An adjusted-matched indirect analysis approach was 
used to compare overall survival (OS) estimates in mNSCLC patients treated with 
erlotinib from SATURN versus pemetrexed patients from JMEN. Patient distributions 
of key characteristics between the two studies were unbalanced; JMEN trial patients 
had a better prognosis at baseline. Patient distributions observed in the pemetrexed 
study for race and smoking status were used to match erlotinib-treated patients using 
patient-level data from the SATURN trial, employing an adjusted matching approach 
to make the populations more comparable. a distribution of survival outcomes was 
derived from each of 1000 repeated random matching samples of the SATURN data, 
with 95% conﬁ dence intervals (CI) around the mean of the aggregate of all observed 
median OS survival estimates generated by ordering the outcome measures and iden-
tifying the 2.5 percentile observations. To indirectly compare treatments, the median 
ratio (MR) for OS was calculated to approximate the hazard ratio. RESULTS: The 
estimated median OS after adjusted-matching was 13.9 months (95% CI 10.9–16.8) 
for erlotinib, compared with the published median OS reported for pemetrexed of 
13.4 months (95% CI: 11.9–15.9). Erlotinib patients had similar median OS compared 
to pemetrexed patients with an MR of 0.96 (0.95, 1.09). CONCLUSIONS: Erlotinib 
and pemetrexed are similarly efﬁ cacious in ﬁ rst-line maintenance NSCLC differing in 
other parameters than efﬁ cacy such as tolerability, administration, and patient 
convenience.
